Back
  • There are no suggestions because the search field is empty.
Aiforia® Breast Cancer Suite

AI for breast cancer diagnostics

Elevate your pathology lab with Aiforia® Breast Cancer Suite – enhancing precision, speed, and diagnostic accuracy with cutting-edge AI technology.

Aiforia® Breast Cancer Suite consists of AI models with an optimized interactive user interface that supports pathologists in the histological grading of breast cancer and in the assessment of breast cancer IHC markers.

Only certain Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries; see details under each AI model.

Contact us
Breast cancer suite

Enhance your pathology workflow with Aiforia

Aiforia® Breast Cancer Suite offers a fully digital cockpit for breast cancer diagnostics, supporting the entire diagnostic workflow.

 

Breast Cancer workflow

 

Breast Cancer Suite: AI models

Aiforia® Breast Cancer Grading
Aiforia® Breast Cancer ER
Aiforia® Breast Cancer PR
Aiforia® Breast Cancer HER2
Aiforia® Breast Cancer Ki67
Aiforia® Lymph Node Metastasis
breast-cancer-grading_image 1

Automates breast cancer grading from H&E-stained whole-slide images (WSI), accurately identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It objectively scores mitotic count, tubular formation, and nuclear pleomorphism, addressing key challenges of manual grading such as variability and time constraints, consistent with the Nottingham Grading System.

Clinical performance highlights
  • Substantially reduces grading time (50% faster)
  • High correlation with expert grading assessments
  • Consistently reproducible, reducing interobserver variability


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Breast ER with AI masks

Automatically detects invasive carcinoma and quantifies ER-positive and negative tumor cells from whole-slide images (WSI) or selected tissue areas, supporting consistent and objective scoring.

Clinical performance highlights
  • Exceptional diagnostic accuracy with high correlation to expert assessments
  • Improved diagnostic consistency with reduced interobserver variability
  • Accelerated workflow with up to 47% faster ER scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Breast PR with AI masks

Automatically detects invasive carcinoma and quantifies PR-positive and negative cells from whole-slide images (WSI) or selected tissue regions, enhancing diagnostic clarity and workflow.

Clinical performance highlights
  • High diagnostic confidence with enhanced interobserver agreement
  • Reliable reproducibility with near-perfect consistency
  • Efficient workflow with approximately 12% faster scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

BrCa_HER2_20x_cropped

Accurately identifies invasive carcinoma and scores HER2 expression in alignment with CAP guidelines,  improving diagnostic reliability and workflow efficiency.

Clinical performance highlights
  • Outstanding sensitivity and precision for confident HER2 classification
  • Enhanced diagnostic consistency with increased interobserver concordance
  • Objective support to identify challenging HER2-low and HER2-ultralow cases


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Breast Ki67 with AI masks

Automatically detects invasive carcinoma and quantifies Ki67-positive and negative tumor cells from whole-slide images (WSI) or targeted image regions, improving diagnostic accuracy and workflow.

Clinical performance highlights
  • High diagnostic accuracy with excellent correlation to expert visual scoring
  • Enhanced diagnostic concordance through improved pathologist agreement
  • Significant time savings, reducing scoring duration by up to 54%
  • Reliable precision with automated hotspot detection for accurate proliferation assessment

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

 

aiforia-lymph-node-metastasis-breast

Supports the detection and quantification of metastases of breast cancer in lymph nodes from whole slide images.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

 

Breast Cancer Suite: AI models

Aiforia® Breast Cancer Grading

breast-cancer-grading_image 1

Automates breast cancer grading from H&E-stained whole-slide images (WSI), accurately identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It objectively scores mitotic count, tubular formation, and nuclear pleomorphism, addressing key challenges of manual grading such as variability and time constraints, consistent with the Nottingham Grading System.

Clinical performance highlights
  • Substantially reduces grading time (50% faster)
  • High correlation with expert grading assessments
  • Consistently reproducible, reducing interobserver variability


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer ER

Breast ER with AI masks

Automatically detects invasive carcinoma and quantifies ER-positive and negative tumor cells from whole-slide images (WSI) or selected tissue areas, supporting consistent and objective scoring.

Clinical performance highlights
  • Exceptional diagnostic accuracy with high correlation to expert assessments
  • Improved diagnostic consistency with reduced interobserver variability
  • Accelerated workflow with up to 47% faster ER scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer PR

Breast PR with AI masks

Automatically detects invasive carcinoma and quantifies PR-positive and negative cells from whole-slide images (WSI) or selected tissue regions, enhancing diagnostic clarity and workflow.

Clinical performance highlights
  • High diagnostic confidence with enhanced interobserver agreement
  • Reliable reproducibility with near-perfect consistency
  • Efficient workflow with approximately 12% faster scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer HER2

BrCa_HER2_20x_cropped

Accurately identifies invasive carcinoma and scores HER2 expression in alignment with CAP guidelines,  improving diagnostic reliability and workflow efficiency.

Clinical performance highlights
  • Outstanding sensitivity and precision for confident HER2 classification
  • Enhanced diagnostic consistency with increased interobserver concordance
  • Objective support to identify challenging HER2-low and HER2-ultralow cases


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer Ki67

Breast Ki67 with AI masks

Automatically detects invasive carcinoma and quantifies Ki67-positive and negative tumor cells from whole-slide images (WSI) or targeted image regions, improving diagnostic accuracy and workflow.

Clinical performance highlights
  • High diagnostic accuracy with excellent correlation to expert visual scoring
  • Enhanced diagnostic concordance through improved pathologist agreement
  • Significant time savings, reducing scoring duration by up to 54%
  • Reliable precision with automated hotspot detection for accurate proliferation assessment

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

 

Aiforia® Lymph Node Metastasis

aiforia-lymph-node-metastasis-breast

Supports the detection and quantification of metastases of breast cancer in lymph nodes from whole slide images.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

 

Why Aiforia?

Products_Clinical

The most comprehensive AI toolkit

Aiforia® Breast Cancer Suite offers advanced tools for histological grading and biomarker detection, ensuring precision and efficiency.

Industry_CRO

Transparent and adjustable results

Review accurate pixel-level results at the highest resolution. The suite improves repeatability and traceability while giving you full control of the results. 

ic_speed_up_pink

High lifetime value

Designed for longevity, Aiforia’s AI models evolve with your lab’s needs, ensuring consistent accuracy and flexibility throughout their lifecycle.

ic_our_ai-1_pink

Seamless two-way integration

Aiforia’s AI models easily integrate with your existing laboratory systems.

Case studies, resources and more

AI for clinical diagnostics

How can AI assist in detecting HER2-low breast cancer

BLOG POST

How can AI assist in detecting HER2-low breast cancer?

HER2-low is an emerging breast cancer patient population that could benefit from anti-HER2 treatment. Read how AI can assist pathologists in its detection.

Read more >

5 reasons to use AI in clinical diagnostics

BLOG POST

5 reasons to use AI in clinical diagnostics

What benefits does AI bring to the digitized pathology workflow in clinical diagnostics? Read our article to find out.

Read more >

Cerba Research case study

CASE STUDY

Cerba Research case study: utilizing AI in Ki-67 quantification in solid tumors

In this study, the results of Ki-67 scoring performed with Aiforia® Platform were compared against three independent pathologists on various solid tumors.

Read the case >

How did the Mayo Clinic choose a vendor for AI in pathology

BLOG POST

How did the Mayo Clinic choose a vendor for AI in pathology?

What to consider when choosing a vendor for AI in pathology? Learn how the Mayo Clinic evaluated platform providers based on six key criteria.

Read more >

 

SEEING IS BELIEVING

Contact us

Want to understand how AI could fit into your pathology workflow?

Our experts can show you the Aiforia® Breast Cancer Suite in action and discuss how it could assist and support your routine practices in breast cancer diagnostics. 

Fill in the contact form to start the discussion.